Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | IGF1R | P08069 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 2/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.37 |
| ▸ | SYK | P43405 | 3/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.32 |
| ▸ | BCL6 | P41182 | 1/20 | 0.32 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3852710 | 0.86 | IGF1R (0.41) | KMT2AIGF1RJAK2NTRK1ROCK2 | |
| SCHEMBL4073673 | 0.84 | IGF1R (0.43) | KMT2AIGF1RNTRK1 | |
| SCHEMBL589661 | 0.84 | IGF1R (0.46) | IGF1RNTRK1 | |
| SCHEMBL4069130 | 0.84 | IGF1R (0.45) | KMT2AIGF1RROCK2 | |
| SCHEMBL3763586 | 0.79 | IGF1R (0.38) | KMT2AIGF1RALDH1A1SYK | |
| SCHEMBL220033 | 0.78 | IGF1R (0.66) | IGF1RJAK2NTRK1 | |
| SCHEMBL4068340 | 0.77 | — | — | |
| SCHEMBL3340680 | 0.75 | NTRK1 (0.42) | NTRK1 | |
| SCHEMBL3339748 | 0.75 | NTRK1 (0.43) | JAK2NTRK1 | |
| SCHEMBL27815652 | 0.74 | IGF1R (0.33) | IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114989-B2 | Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2012-02-14 | — | — | US | disclosed |
| US-20100210648-A1 | PYRAZOLYLAMINOPYRIMIDINE DERIVATIVES USEFUL AS TYROSINE KINASE INHIBITORS | ASTRAZENECA R&D (SE) | 2010-08-19 | — | — | US | disclosed |
| EP-1686999-B1 | PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTRAZENECA AB (SE) | 2009-07-01 | — | — | EP | disclosed |
| US-20080287437-A1 | Pyrazolylaminopyrimidine Derivatives Useful as Tyrosine Kinase Inhibitors | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287437-A1 | Pyrazolylaminopyrimidine Derivatives Useful as Tyrosine Kinase Inhibitors | ABL1, FLT3, ERBB2 | KMT2A 1536/4885IGF1R 407/4885ALDH1A1 1326/4885 |
| US-20100210648-A1 | PYRAZOLYLAMINOPYRIMIDINE DERIVATIVES USEFUL AS TYROSINE KINASE INHIBITORS | ABL1, FLT3, ERBB2 | KMT2A 1536/4885IGF1R 407/4885ALDH1A1 1326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.